- Home
- SEED vs NERV Comparison
SEED vs NERV Comparison
Compare SEED & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- NERV
- Stock Information
- Founded
- SEED 1997
- NERV 2007
- Country
- SEED China
- NERV United States
- Employees
- SEED N/A
- NERV N/A
- Industry
- SEED Farming/Seeds/Milling
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- SEED Consumer Staples
- NERV Health Care
- Exchange
- SEED Nasdaq
- NERV Nasdaq
- Market Cap
- SEED 17.1M
- NERV 18.3M
- IPO Year
- SEED N/A
- NERV 2014
- Fundamental
- Price
- SEED $2.11
- NERV $2.19
- Analyst Decision
- SEED
- NERV Hold
- Analyst Count
- SEED 0
- NERV 1
- Target Price
- SEED N/A
- NERV $5.00
- AVG Volume (30 Days)
- SEED 20.9K
- NERV 14.3K
- Earning Date
- SEED 12-31-2024
- NERV 11-05-2024
- Dividend Yield
- SEED N/A
- NERV N/A
- EPS Growth
- SEED N/A
- NERV N/A
- EPS
- SEED 1.21
- NERV N/A
- Revenue
- SEED $16,516,031.00
- NERV N/A
- Revenue This Year
- SEED N/A
- NERV N/A
- Revenue Next Year
- SEED N/A
- NERV N/A
- P/E Ratio
- SEED $1.84
- NERV N/A
- Revenue Growth
- SEED 64.93
- NERV N/A
- 52 Week Low
- SEED $1.37
- NERV $2.06
- 52 Week High
- SEED $6.38
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- SEED 30.82
- NERV 45.26
- Support Level
- SEED $2.41
- NERV $2.08
- Resistance Level
- SEED $2.65
- NERV $2.32
- Average True Range (ATR)
- SEED 0.18
- NERV 0.13
- MACD
- SEED -0.04
- NERV 0.01
- Stochastic Oscillator
- SEED 1.54
- NERV 33.33
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.